WeightSnapWhat Is BPC-157? Benefits, Research, and Status
BPC-157 is one of the most-discussed peptides in the recovery world. Here is what it actually is, what the research does and does not show, where it stands with regulators in 2026, and how it turns up inside popular blends.
What BPC-157 is
BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, a chain of 15 amino acids, based on a partial sequence of a protective protein found naturally in human gastric juice. It was first isolated and characterized in the 1990s by a Croatian research group, and it has since built up one of the larger preclinical literatures of any "recovery" peptide, with dozens of published animal studies.
Because it comes from a gut-protective protein, a lot of the early interest was in the digestive tract, but the research has since branched into soft-tissue and musculoskeletal repair, which is where most of its popular reputation now comes from.
What the research examines (and the big caveat)
In preclinical models, researchers have studied BPC-157 for several things. Framed accurately, these are areas of investigation, not established human benefits:
- Tendon and ligament healing. In lab studies, BPC-157 increased the migration and outgrowth of tendon fibroblasts and raised expression of growth-factor receptors, which are steps involved in repair.
- Angiogenesis. It has been shown in models to promote the formation of new blood vessels (via receptors such as VEGFR2), which matters because tendons and ligaments have famously poor blood supply.
- Gut-lining repair. Consistent with its origin, it has been studied for protective and healing effects in the gastrointestinal tract.
- Anti-inflammatory and neuroprotective effects. Broader "body protection" effects have been examined across a range of tissues.
Regulatory status in 2026
This is a fast-moving picture, so it is dated on purpose. As of mid-2026:
- BPC-157 is not FDA-approved for any indication and has not completed FDA clinical trials.
- It was placed on the FDA's 503A Category 2 restricted list in 2023 over safety and data concerns, then removed from that list, and it is scheduled for a Pharmacy Compounding Advisory Committee (PCAC) review on July 23-24, 2026, which will consider BPC-157 bulk substances for compounding.
- It is unscheduled under the US Controlled Substances Act and is sold Research Use Only.
- It is on the World Anti-Doping Agency prohibited list, so it is disqualifying for tested athletes.
Because the compounding rules around it are actively being decided in 2026, treat any seller's claim that it is "now fully legal" with caution, and check the current FDA position directly rather than trusting a page like this one to stay current.
How BPC-157 is dosed
There is no established human dose, for the simple reason that BPC-157 has not been through human clinical trials. Amounts discussed in the research community are usually in the microgram range, but a specific dose is a decision for a licensed provider, not something a reference page should hand out. That is the describe-not-prescribe line, and this page stays on the right side of it.
What is safe to help with is the arithmetic. If you are reconstituting a vial and need to convert milligrams, bacteriostatic water, and syringe units, that is pure math: the free reconstitution calculator handles a single-peptide vial, and the blend calculator handles a multi-peptide vial. Neither one recommends a dose.
BPC-157 in blends
BPC-157 rarely travels alone in the community. It is a core ingredient in several popular blends: Wolverine (commonly BPC-157 with TB-500), and the GLOW and KLOW blends (which add GHK-Cu, and, for KLOW, KPV). In a blend, every syringe draw contains all the components in a fixed ratio, and BPC-157 is typically dosed in micrograms while a component like GHK-Cu is in milligrams, which is exactly the kind of thing that trips people up. The blend calculator shows the per-component amount for whatever is on your vial label.
Frequently asked questions
What is BPC-157?
A synthetic 15-amino-acid peptide based on a protein from gastric juice, first characterized in the 1990s. One of the most-studied peptides in preclinical recovery research. Sold as a research chemical, not an approved medicine.
What is BPC-157 used for in research?
Preclinical (mostly rodent) studies have examined it for tendon and ligament healing, gut-lining repair, angiogenesis, and anti-inflammatory effects. These are research findings in animals, not confirmed human benefits.
Is BPC-157 FDA approved?
No. As of mid-2026 it is not approved and has no completed FDA trials. It was removed from the FDA 503A Category 2 list and is scheduled for a Pharmacy Compounding Advisory Committee review on July 23-24, 2026. Its status is changing, so verify the current FDA position.
Is BPC-157 legal?
It is unscheduled under the Controlled Substances Act and sold Research Use Only; it is not approved to market for human treatment, and it is banned by WADA for athletes. Not legal advice.
How is BPC-157 dosed?
There is no established human dose (no completed human trials). Community amounts are usually in micrograms, but dosing is a provider decision, not something this page specifies. For reconstitution arithmetic only, use the reconstitution or blend calculator.
WeightSnap is a tracking tool, not medical advice. This page is a technical reference about a research-chemical peptide. It does not recommend using BPC-157, provides no dosing protocol, and should not replace guidance from a licensed healthcare provider. Regulatory details are accurate to the best of our knowledge as of July 2026 and are subject to change.